Letters to the Editor

Markers of bone resorption in bisphosphonate therapy of Paget's disease

Sirs,

Bone turnover markers are used in diagnosis but particularly in the therapeutic monitoring of Paget's disease (1, 2). In recent years the evaluation of serum and urine N (NTx) and C (CTx) telopeptides of type I collagen has assumed particular importance. NTx released into the bloodstream and eliminated by the kidney without further metabolism are sensitive indicators of bone mass variation; CTx β isomerized fragments expressing the historical memory of the bone could be utilized as an index of bone resorption.

We studied 10 patients with Paget's disease – 4 women (age 60-72 yr.; average age: 68) and 6 men (age 64 - 78 yr.; average age: 76) – who were treated with Risendronate, in order to evaluate the utility of some of the parameters of bone resorption (sCTx, uNTx and sNTx) in the management of therapy. All subjects provided written informed consent before enrolling in the study.

The diagnosis of Paget's disease was made according to clinical-rheumatological tests: tAP> 270 U/L, x-rays of the involved bone areas, and three-phase bone scintigraphy. All patients had poliostotic Paget's disease and normal liver and renal function and were treated with oral Risendronate (30 mg/day) for 2 months. The drug was taken with water in the morning on an empty stomach, the patients then waiting more than 60 minutes before ingesting any food or drink other than water.

The bone turnover markers were evaluated on morning samples obtained between 8:00 and 9:00 a.m. after an overnight fast, before and 30 days after therapy. Urine parameters were evaluated on the first voided urine of the morning and results were expressed as urinary creatinine excretion to reduce the variability due to diuresis. All samples were divided into aliquots and stored at -20°C for a maximum of 30 days until assayed. Statistical analysis was performed using Student's t-test. Laboratory methods and the mean values of bone resorption markers before and after therapy are reported in Table I.

Regarding bone formation markers, the mean total serum alkaline phosphatase (tAP) levels were 419.50±259.25U/Lat baseline and 191.33 ± 38.94 U/Lafter therapy; mean serum levels of bone alkaline phosphatase (bAP) were 69.75 ± 38.43 ng/ml at baseline and 36.50 ± 29.82 ng/ml after therapy; one patient with symptomatic Paget's disease (documented by radiography and bone scintigraphy) showed high levels of bAP despite a normal tAP.

Before starting therapy, resorption parameters were above the normal range in all the patients examined; one month after the end of treatment sCTx, uNTX and sNTx were significantly reduced. In particular, sCTx returned to the normal range in all patients and showed the highest statistical significance (Table I). After beginning therapy, a significant reduction in the markers both of resorption (within 4-6 weeks) and of neoformation (within 2-3 months) was demonstrated.

Table I. Values of the parameters examined before and after therapy.

Biochemical markers	Baseline (mean ± SD)	30 days after therapy (mean ± SD)	p
uNTX	236.25 ± 141.13	75.50 ± 80.31	0.09
sNTX	42.59 ± 12.15	21.00 ± 14.02	0.05
sCTX	7776.00 ± 2929.39	1772.50 ± 1553.58	0.01

uNTx: urine cross linked N telopeptides of type I collagen (nM Bone Collagen Equivalent/mM Creatinine); normal value: male 5-65, female 3-51; competitive inhibition enzyme linked immunosorbent assay; CVwithin run 4.5% (osteomark Ostex International Inc., Seattle, USA).
sNTx: serum cross linked N telopeptides of type I collagen (nMBone Collagen Equivalent/L); normal value: male 5.4 - 24; female 6.2 - 19; competitive inhibition enzyme linked immunosorbent assay; CVwithin run 4.6% (osteomark Ostex International Inc., Seattle, USA).
sCTx: serum cross linked C telopeptides of type I collagen (pmol/L); normal value: male 1100-3700, premenopausal female 1300-3400, menopausal female 1800-5400; one-step ELISAwith monoclonal antibodies; CVwithin run 5.2% (Nordic Bioscience Diagnostics Denmark).

Some authors (3-7) have demonstrated that sCTx is a highly sensitive biological marker to assess the efficacy of anti-resorptive therapy, and it has become the most widely used laboratory parameter in clinical practice. Alvarez (3) investigated the individual biological variability of the markers of bone turnover in patients with stable and non-symptomatic Paget's disease. Over a period of one year the markers of bone resorption showed a very low variability: in particular, the sCTx showed the lower within-subject variability. Recently the development of a new method of evaluating sCTX has permitted a further reduction in individual variation. Furthermore, some authors (8, 9) have standardized the method of obtaining samples of serum in which the sCTx shows the lowest biological variation.

Our study shows that sCTX is a sensitive marker of bone resorption in the management of bisphosphonate therapy in Paget's disease.

E. CACACE, *MD* L. URAS, *BS*
V. RUGGIERO, *BS* G. PERPIGNANO, *MD*
C. MATULLI, *MD*

Rheumatology Unit, Department of Internal Medicine University General Hospital, Cagliari, Italy.

Address correspondence to: Enrico Cacace, MD, Cattedra di Reumatologia I, Policlinico Universitario, SS 554, bivio Sestu, Monserrato, 09100 Cagliari, Italy.
E-mail: cacace@pacs.unica.it

References

1. MEUNIER PJ: Paget's disease: Treatment results and expectations with present therapies. *J Bone Miner Res* 1999; 14 (Suppl. 2): 70-3.
2. DELMAS P, MEUNIER P: The management of Paget's disease of bone. *N Engl J Med* 1997; 8: 558-66.
3. ALVAREZ L, RICÒS C, PERIS P *et al.*: Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. *Bone* 2000; 26: 571-6.
4. CHRISTGAU S, ROSENQUIST C *et al.*: Clinical evaluation of the serum cross laps One Step Elisa, a new assay measuring the serum concentration of bone derived degradation products derived from the C terminal telopeptide of type I collagen. *Clinical Chemistry* 1998; 44: 2290-301.
5. ALVAREZ L, GUANABENS N, PERIS P *et al.*: Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. *Bone* 2001; 29: 447-52.
6. D'AMELIO P, ISAIA G: Il laboratorio e i markers. *In* ISAIA G: *Le Malattie del Metabolismo Minerale*. Torino, Centro Scientifico Editore, 2000: 31-41.
7. EASTEL R: Biochemical markers of bone turnover in Paget's disease of bone. *Bone* 1999; 24: 49s-50s.
8. CHRISTAGAU S, BITSCH-JENSEN O, HANOVER BJARNASON N *et al.*: Serum cross-laps in monitoring the response in Individuals undergoing antiresorptive therapy. *Bone* 2000; 26: 505-11.
9. SCHLEMMER A, HASSAGER C: Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. *Eur J Endocrinol* 1999; 140: 332-7.

Infliximab induced lupus in patients with rheumatoid arthritis

Sirs,

Treatment of rheumatoid arthritis (RA) with either etanercept or infliximab has been associated with the development of antinuclear antibodies (1) and anti- ds DNAantibodies of the IgM class (2), although clinical drug-induced lupus (DIL) has been occasionally reported (3,4). We describe here two patients with seropositive rheumatoid arthritis who developed clinical and serological signs of lupus while treated with infliximab.

Patient 1 was a 61-year-old woman with a 10-year history of inadequately controlled RAdespite consecutive and combined treatment with MTX, azathioprine, hydroxychloroquine, sulfasalazine, cyclosporine and low doses corticosteoids. On September 2001, while on prednisone and MTX, she started treatment with infliximab at a dosage of 3 mg/kg on days 1, 14 and 45. After the second infusion, she presented significant improvement, with a reduction in the number of tender and swollen joints (from 12 to 5 and from 8 to 2, respectively), a decreased duration of morning stiffness, and decreased ESR and serum CRP levels.